Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,450 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C, Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME, Terstappen LW, de Bono JS. Attard G, et al. Among authors: molina a, a hern r. Cancer Res. 2009 Apr 1;69(7):2912-8. doi: 10.1158/0008-5472.CAN-08-3667. Cancer Res. 2009. PMID: 19339269 Free article.
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.
Scher HI, Heller G, Molina A, Attard G, Danila DC, Jia X, Peng W, Sandhu SK, Olmos D, Riisnaes R, McCormack R, Burzykowski T, Kheoh T, Fleisher M, Buyse M, de Bono JS. Scher HI, et al. Among authors: molina a. J Clin Oncol. 2015 Apr 20;33(12):1348-55. doi: 10.1200/JCO.2014.55.3487. Epub 2015 Mar 23. J Clin Oncol. 2015. PMID: 25800753 Free PMC article. Clinical Trial.
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS. Attard G, et al. Among authors: molina a, a hern r. J Clin Oncol. 2009 Aug 10;27(23):3742-8. doi: 10.1200/JCO.2008.20.0642. Epub 2009 May 26. J Clin Oncol. 2009. PMID: 19470933 Free PMC article. Clinical Trial.
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS. Reid AH, et al. Among authors: molina a. J Clin Oncol. 2010 Mar 20;28(9):1489-95. doi: 10.1200/JCO.2009.24.6819. Epub 2010 Feb 16. J Clin Oncol. 2010. PMID: 20159823 Free PMC article. Clinical Trial.
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate.
Attard G, de Bono JS, Logothetis CJ, Fizazi K, Mukherjee SD, Joshua AM, Schrijvers D, van den Eertwegh AJ, Li W, Molina A, Griffin TW, Kheoh T, Ricci DS, Zelinsky K, Rathkopf DE, Scher HI, Ryan CJ. Attard G, et al. Among authors: molina a. Clin Cancer Res. 2015 Apr 1;21(7):1621-7. doi: 10.1158/1078-0432.CCR-14-1961. Epub 2015 Jan 15. Clin Cancer Res. 2015. PMID: 25593303 Free PMC article. Clinical Trial.
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.
Lorente D, Olmos D, Mateo J, Bianchini D, Seed G, Fleisher M, Danila DC, Flohr P, Crespo M, Figueiredo I, Miranda S, Baeten K, Molina A, Kheoh T, McCormack R, Terstappen LW, Scher HI, de Bono JS. Lorente D, et al. Among authors: molina a. Eur Urol. 2016 Dec;70(6):985-992. doi: 10.1016/j.eururo.2016.05.023. Epub 2016 Jun 9. Eur Urol. 2016. PMID: 27289566 Free PMC article.
The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population.
Heller G, Fizazi K, McCormack R, Molina A, MacLean D, Webb IJ, Saad F, de Bono JS, Scher HI. Heller G, et al. Among authors: molina a. Clin Cancer Res. 2017 Apr 15;23(8):1967-1973. doi: 10.1158/1078-0432.CCR-16-1224. Epub 2016 Sep 27. Clin Cancer Res. 2017. PMID: 27678453 Free PMC article. Clinical Trial.
Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer.
Goodman OB Jr, Flaig TW, Molina A, Mulders PF, Fizazi K, Suttmann H, Li J, Kheoh T, de Bono JS, Scher HI. Goodman OB Jr, et al. Among authors: molina a. Prostate Cancer Prostatic Dis. 2014 Mar;17(1):34-9. doi: 10.1038/pcan.2013.41. Epub 2013 Oct 1. Prostate Cancer Prostatic Dis. 2014. PMID: 24080993 Free PMC article. Clinical Trial.
Reply to A. Addeo and A. Bahl.
Scher HI, Heller G, Molina A, Kheoh T, de Bono JS. Scher HI, et al. Among authors: molina a. J Clin Oncol. 2016 Feb 1;34(4):387-8. doi: 10.1200/JCO.2015.64.6562. Epub 2015 Nov 23. J Clin Oncol. 2016. PMID: 26598756 No abstract available.
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.
Heller G, McCormack R, Kheoh T, Molina A, Smith MR, Dreicer R, Saad F, de Wit R, Aftab DT, Hirmand M, Limon A, Fizazi K, Fleisher M, de Bono JS, Scher HI. Heller G, et al. Among authors: molina a. J Clin Oncol. 2018 Feb 20;36(6):572-580. doi: 10.1200/JCO.2017.75.2998. Epub 2017 Dec 22. J Clin Oncol. 2018. PMID: 29272162 Free PMC article.
1,450 results